Env-targeting bNAbs have been able to reduce viral reservoirs in preclinical models of persistent HIV infection, as measured by declines in proviral DNA and delays in viral rebound [23,24,62,63]. The gene discussed is ERVW-1; the disease is HIV infectious disease.